GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy

Source: 
Endpoints
snippet: 

GW Pharmaceuticals can now boast about its fifth straight successful Phase III trial for its cannabinoid drug Epidiolex.